drugset / Trial / NCT03294161
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
Phase 2
Completed
50 enrolled
Hospital Universitário Professor Edgard Santos
Conselho Nacional de Desenvolvimento Científico e Tecnológico · collabFederal University of Bahia · collabPontificia Universidade Católica do Rio Grande do Sul · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
A clinical trial to asses efficacy and safety of Transition-state Analog Inhibitor of Human Purine Nucleoside Phosphorylase for topical use associated standard antimonial in the treatment of Cutaneous Leishmaniasis in Bahia, Brazil.
Timeline
- Start
- 2014-12
- Primary completion
- 2017-04
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immucillin DI4G | Unknown | 2 % | Topical |
| Comparator | Meglumine antimonate | Other / unclassified | 20 mg/kg | Intravenous |